Quarterly ResultAug 13, 2026, 04:13 PM
Kyntra Bio Q2 Net Income $12.0M, EPS $2.96; Business Update
AI Summary
Kyntra Bio reported its second quarter 2026 financial results, achieving a net income from continuing operations of $12.0 million, or $2.96 per basic and diluted share, a significant improvement from a net loss of $13.7 million in the prior year period. Total revenue from continuing operations for the quarter was $(1.5) million. The company also provided business updates, confirming that the interim analysis for its Phase 2 FG-3246 trial and the initiation of the Phase 3 roxadustat study are both on track for Q4 2026. Kyntra Bio ended the quarter with $95.7 million in cash, cash equivalents, investments, and accounts receivable, which is expected to fund operating plans into 2028.
Key Highlights
- Net income from continuing operations was $12.0 million for Q2 2026, compared to a net loss of $13.7 million in Q2 2025.
- Net income per basic and diluted share was $2.96 for Q2 2026, compared to a net loss of $3.38 in Q2 2025.
- Total revenue from continuing operations was $(1.5) million for Q2 2026, down from $1.3 million in Q2 2025.
- Cash, cash equivalents, investments, and accounts receivable totaled $95.7 million as of June 30, 2026.
- Interim analysis for the Phase 2 trial of FG-3246 is on track for Q4 2026.
- Goal to initiate the registrational Phase 3 study for roxadustat in Q4 2026.
- Company expects cash, cash equivalents, investments, and accounts receivable to fund operations into 2028.
Price Impact
More from KYNB